Exelixis’s Cabometyx continues to drive revenue growth, prompting a raised 2024 forecast to $2.15–$2.2 billion. Read my EXEL ...

Operator Good day, ladies and gentlemen, and welcome to Exelixis' third quarter 2024 financial results conference call. My ...

Positive outcomes from the phase 3 PSMAfore study (NCT04689828), data for which were first presented at the 2023 European Society for Medical Oncology (ESMO) Annual Congress, have led to great ...

The Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD are joined by Rana McKay, MD, to review data from three key clinical trials in GU cancer following updates at ESMO 2023. Key Data Updates ...

At ESMO 2024, Bayer will present key results from the Phase III ... offers potential for improving outcomes in PSMA-positive mCRPC patients. Proffered Paper Session 1: GU Tumours, Non-Prostate LBA73 - ...

Now, new data from the POD1UM-303 study reported at ESMO suggests the company could resurrect the SCAC indication and move Zynyz into the first-line setting to boot. Given in combination with ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...

There were 137 patients included in this study with a median age of 71.8 years (range 50.1-92.8). There were 77.4% of patients that presented de novo stage IV, 16.1% with visceral metastasis, and 53.3 ...

The following abstracts showcase the top cutting-edge research presented at the European Society for Medical Oncology (ESMO) Congress 2024. Topics covered include the use of AI in breast cancer ...